Bertrand B. Coiffier
Advanced in Chronic B-Cell Leukemia (CBCL)

Bertrand B. Coiffier

Pierre-la-treiche, FR 
Advanced in Chronic B-Cell Leukemia (CBCL)
Pierre-la-treiche, FR 
OverviewLocationsClinical Research

Overview

Bertrand Coiffier practices in Pierre-la-treiche, France. Mr. Coiffier is rated as an Advanced expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and B-Cell Lymphoma.

His clinical research consists of co-authoring 161 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles in the study of Chronic B-Cell Leukemia (CBCL).

Gender
Male

Locations

Pierre-la-treiche, France
Other Locations
Lyon, 69002, France
Rouen, France
Dijon, France
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Lenalidomide and GA101
Study Phase: Phase 1/Phase 2
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: Romidepsin, CHOP
Study Phase: Phase 3
Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation
Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation
Enrollment Status: Completed
Publish Date: December 07, 2021
Intervention Type: Drug
Study Drugs: Brentuximab, Etoposide, Carboplatin, Ifosfamide
Study Phase: Phase 1/Phase 2
STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)
STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)
Enrollment Status: Completed
Publish Date: July 26, 2021
Intervention Type: Drug
Study Phase: Phase 2
Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line
Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line
Enrollment Status: Completed
Publish Date: July 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
Randomized Phase III Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+
Randomized Phase III Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+
Enrollment Status: Completed
Publish Date: July 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma
A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: January 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

161 Total Publications

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma.
Resources-Stratified Guidelines for Classical Hodgkin Lymphoma.
Journal: International journal of environmental research and public health
Published: December 19, 2019

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Coiffier's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile